On November 18, the EVP & Chief Comm & Ops Ofcr of Mallinckrodt (MNKKQ), Hugh O’neill, sold shares of MNKKQ for $90.
This is O’neill’s first Sell trade following 3 Buy transactions. In addition to Hugh O’neill, 2 other MNKKQ executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.42 and a one-year low of $0.09.
Based on 3 analyst ratings, the analyst consensus is Hold with an average price target of $1.50, reflecting a -93.7% downside.
The insider sentiment on Mallinckrodt has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.
